Kura Oncology. has filed a patent for a method of treating head and neck squamous cell carcinoma (HNSCC) using tipifarnib in combination with a PI3K inhibitor like alpelisib. The method involves administering specific doses of the two drugs to patients. GlobalData’s report on Kura Oncology gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kura Oncology Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kura Oncology, Cancer treatment biomarkers was a key innovation area identified from patents. Kura Oncology's grant share as of January 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.

Combination treatment for head and neck cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Kura Oncology Inc

A recently filed patent (Publication Number: US20240024301A1) outlines a method for treating head and neck squamous cell carcinoma (HNSCC) in patients. The method involves administering a combination of tipifarnib and 10-400 mg of alpelisib to the patient. Additionally, the patent describes a method for mitigating or overcoming cetuximab-resistance in HNSCC patients who are currently or were previously treated with cetuximab by administering tipifarnib and alpelisib.

Furthermore, the patent details various dosing regimens and administration schedules for tipifarnib and alpelisib, including specific doses and frequencies. The method aims to delay, halt, or prevent the progression of HNSCC, reduce the severity of associated symptoms, and address specific genetic mutations or alterations in the cancer cells. The patent also mentions the potential benefits of the method in terms of increasing Time To Progression (TTP), Progression Free Survival (PFS), and overall response rates compared to other therapies. Additionally, a pharmaceutical kit containing the necessary compositions for the treatment is also described in the patent.

To know more about GlobalData’s detailed insights on Kura Oncology, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies